Feds Shut Down Off-Label Bone Graft Probe, Medtronic Says

Law360, New York (May 16, 2012, 8:10 PM EDT) -- Federal prosecutors have ended their civil and criminal investigation into allegations of off-label marketing of Medtronic Inc.’s Infuse bone graft product, the company said Wednesday, days after a whistleblower False Claims Act suit accusing it of paying kickbacks to promote off-label use was unsealed.

Medtronic received its first Infuse-related subpoena from the U.S. Attorney’s Office for the District of Massachusetts in October 2008. The medical device giant revealed the U.S. Department of Justice investigation the following month, leading to increased scrutiny from government entities, as well...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.